Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Crism Therapeutics's share price for the quarter that ended in Jun. 2024 was £0.0525. Crism Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2024 was 32.68 Mil. Therefore, Crism Therapeutics's market cap for the quarter that ended in Jun. 2024 was £1.72 Mil.
Crism Therapeutics's quarterly market cap
declined
from Jun. 2023 (£3.13 Mil) to Dec. 2023 (£1.25 Mil) but then
increased
from Dec. 2023 (£1.25 Mil) to Jun. 2024 (£1.72 Mil).
Crism Therapeutics's annual market cap
declined
from Dec. 2021 (£23.53 Mil) to Dec. 2022 (£13.93 Mil) and
declined
from Dec. 2022 (£13.93 Mil) to Dec. 2023 (£1.25 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Crism Therapeutics's Enterprise Value for Today is £1.24 Mil.
Crism Therapeutics Market Cap Historical Data
The historical data trend for Crism Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Crism Therapeutics's Market Cap
For the Biotechnology subindustry, Crism Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crism Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crism Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Crism Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Crism Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crism Therapeutics (LSE:CRTX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Crism Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Crism Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:CRTX has been successfully added to your 